Carregant...
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12
The pharmacokinetics of apremilast and its major metabolite M12 were evaluated in subjects with varying degrees of renal impairment. Men and women with renal impairment (estimated glomerular filtration rate, 60‒89 mL/min [mild, n = 8], 30‒59 mL/min [moderate, n = 8], or <30 mL/min [severe, n = 8]...
Guardat en:
| Publicat a: | Clin Pharmacol Drug Dev |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5132082/ https://ncbi.nlm.nih.gov/pubmed/27870479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.256 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|